

## SNMMI New Fellows Honored

At its 2017 Annual Meeting in Denver, CO, SNMMI recognized 7 new SNMMI Fellows during a special plenary session on June 12. The SNMMI Fellowship was established in 2016 to recognize distinguished service to the society as well as exceptional achievement in the field of nuclear medicine and molecular imaging. It is one of the most prestigious formal recognitions available to long-time SNMMI members.

All past SNMMI presidents were granted fellowship as part of the inaugural group of fellows at the 2016 Annual Meeting. At the 2017 meeting, 2016–2017 SNMMI President Sally W. Schwarz,

MS, RPh, BCNP, joined the new fellowship ranks. She is a professor of radiology, director of PET Radiopharmaceutical Production, and codirector of the Cyclotron Facility at Washington University School of Medicine (St. Louis, MO). Also recognized as new SNMMI fellows were: S. James Adelstein, MD, PhD, Paul C. Cabot Professor of Medical Biophysics (emeritus), Harvard Medical School (Boston, MA); Patrick M. Colletti, MD, professor of radiology, medicine, biokinesiology, and pharmaceutical sciences, Keck School of Medicine, University of Southern California (Los Angeles); Diwakar M. Jain, MD, professor of cardiovascular

medicine and director of nuclear cardiology, New York Medical College, Westchester Medical Center (Valhalla); John W. Keyes, MD, professor of radiology emeritus, Wake Forest University Bowman Gray School of Medicine (Winston-Salem, NC); Christopher J. Palestro, MD, professor of radiology, Hofstra Northwell School of Medicine, Hofstra University (Hempstead, NY), and chief of nuclear medicine and molecular imaging at Northwell Health; and Andrew T. Taylor, Jr., MD, professor of radiology and imaging sciences, Emory University School of Medicine (Atlanta, GA).

Selection of SNMMI fellows is based on documented excellence in volunteer service to the society and at least 1 of 3 additional areas: excellence in scientific discovery and innovation, educational efforts in nuclear medicine and molecular imaging, or clinical practice of nuclear medicine and molecular imaging. SNMMI fellowship is recognized with the designation FSNMMI.



**SNMMI President Ben Greenspan, MD, MS (far left), with the new SNMMI fellows (left to right): Patrick Colletti, MD; Diwakar Jain, MD; John Keyes, MD; Christopher Palestro, MD; Andrew Taylor, MD; and Sally Schwarz, MS, RPh, BCNP. Not pictured: S. James Adelstein, MD, PhD.**

## USP to Establish New General Chapter on Compounding

On June 1, the U.S. Pharmacopeia (USP) announced plans to create a new General Chapter <825> *Compounding—Radiopharmaceuticals*, with an objective “to provide clear and effective USP public standards that meet patient and practitioner needs for compounded sterile radiopharmaceuticals today and in the future.” The proposed new general chapter will delineate compounding activities for radiopharmaceuticals and provide standards associated with these activities. In a general announcement, USP noted that the current Chemical Medicines Monographs 4 Expert Committee will form a new expert panel, which will be charged with drafting <825> *Compounding—Radiopharmaceuticals*. The resulting proposal will be published in *Pharmacopeal Forum* for public comments in late 2018.

In its announcement, USP noted that, since 2004, General Chapter <797> *Pharmaceutical Compounding—Sterile Preparations* has described standards for the entire spectrum of compounded sterile preparations. Standards for radiopharmaceuticals have been addressed at various levels within <797>, but it has

been “difficult to develop and maintain standards for radiopharmaceuticals in this manner due to the scope of <797> and the unique characteristics of radiopharmaceuticals.” In February 2017, the USP hosted a roundtable discussion on compounding standards for radiopharmaceuticals. Participants discussed potential approaches to address the challenges associated with this class of products. Stakeholders from the nuclear medicine community, including SNMMI, strongly favored development of a new general chapter for radiopharmaceutical compounding.

SNMMI has been an integral part of this effort, and on June 2 commended USP for its decision to establish a new chapter. USP, in its comments on anticipated proposed design phase activities, wrote, “The background and concepts in this new general chapter are included in a white paper that was written by the Committee on Radiopharmaceuticals, which is a standing committee within the SNMMI.” The full SNMMI white paper is available at: [http://snmmi.files.cms-plus.com/SNMMI-USP-Recommendations-Final\\_2016.pdf](http://snmmi.files.cms-plus.com/SNMMI-USP-Recommendations-Final_2016.pdf).